American technology firm Medidata, a subsidiary of Dassault Systèmes, has expanded its partnership with biopharmaceutical company Horizon Therapeutics to improve efficiencies and outcomes in clinical trials.
Under the expanded partnership, Medidata will provide a wide range of solutions for Horizon’s clinical research needs in various therapeutic areas, such as ophthalmology, rheumatology, and nephrology.
Medidata co-founder and co-CEO Tarek Sherif said: “We’re delighted to be a key partner to Horizon and its exceptional journey that benefits patients by advancing science and treatments.
“Medidata’s goal is to facilitate Horizon’s path forward using advanced analytics and technology. We’re looking forward to further supporting the company’s vision, especially as it relates to improving efficiencies and speeding the completion of clinical studies.”
Using Medidata’s most used platform, Medidata Rave Clinical Cloud, Horizon will access a broad range of clinical trial solutions.
The Medidata platform is used to accelerate clinical research with a set of applications such as data capture, data management, trial planning, as well as trial management.
Furthermore, Horizon will use Medidata’s Intelligent Trials product to bring ‘cross-industry real-time performance metrics, predictive models, and forecasting capabilities’ for clinical trial planning as well as its execution.
Built on the industry’s broadest clinical trial dataset, Intelligent Trials brings artificial intelligence (AI), partnered with advanced analytics.
It covers over six million patients in more than 22,000 clinical trials.
Horizon Therapeutics research and development executive vice-president Karin Rosén said: “Through the use of the Medidata technologies, we have been able to create a more efficient, manageable and cost-effective clinical trial process, which led us to expand this productive relationship.
“As our clinical needs have evolved, the Medidata platform gives us the flexibility and agility to scale and grow.”
In July last year, Medidata said it would support clinical trials of Moderna’s Covid-19 vaccine candidate ‘mRNA-1273’ after the companies entered a partnership.